Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tranexamic acid controlled release - Nordic Pharma

Next Previous
X
Search
Drug Profile

Tranexamic acid controlled release - Nordic Pharma

Alternative Names: Lysteda; Tranexamic acid SR; Tranexamic acid sustained-release; XP-12B

Latest Information Update: 07 Mar 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xanodyne Pharmaceuticals
  • Class Amines; Anti-infectives; Anti-inflammatories; Antifibrinolytics; Antihaemorrhagics; Cardiovascular therapies; Cyclohexanecarboxylic acids; Skin disorder therapies; Small molecules
  • Mechanism of Action Antifibrinolytic agents; Plasminogen activator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Menorrhagia

Most Recent Events

  • 04 Mar 2024 Amring Pharmaceuticals is now called Nordic Pharma
  • 23 Aug 2021 Tranexamic acid licensed to Pierre Fabre in Mexico
  • 01 Dec 2020 Amring Pharmaceuticals acquires from tranexamic acid controlled-release from Ferring Pharmaceuticals

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top